DnaJC25 Inhibitors

The chemical class termed DnaJC25 Inhibitors encompasses a range of compounds that can exert an effect on the protein folding processes within the cell by indirectly modulating the activity of the DnaJC25 protein, a member of the Hsp40 family of co-chaperones. These compounds are not inhibitors in the classical sense of directly binding to and obstructing the functional activity of DnaJC25. Instead, they operate within the broader cellular framework that oversees protein homeostasis, also known as proteostasis, which includes an intricate network of molecular chaperones and proteolytic systems that together maintain the health of the cellular proteome. Among these compounds, Hsp90 inhibitors such as Geldanamycin, Radicicol, 17-AAG, PU-H71, and Novobiocin, can perturb the stabilizing interaction between Hsp90 and its client proteins, which can have a cascading effect on the function of co-chaperones like DnaJC25.

By destabilizing these interactions, these compounds can increase the load of unfolded or misfolded proteins, thereby indirectly impacting DnaJC25, which may become overburdened or dysregulated. Other compounds like Tunicamycin, by inhibiting N-linked glycosylation, can cause a buildup of glycoproteins that require proper folding, which can affect the cellular demand for chaperone activity. The V-ATPase inhibitor Concanamycin A and the lysosomotropic agent Chloroquine can disrupt cellular compartment pH, affecting the environment necessary for optimal protein folding and possibly increasing the requirement for DnaJC25's involvement in these processes. Moreover, proteasome inhibitors like MG132 and Bortezomib can lead to an accumulation of proteins destined for degradation, again potentially enhancing the need for DnaJC25 activity to manage this protein load.